COR logo

CENCORA INC

CORNYSE
πŸ† #225 by market capEarnings Nov 4 Β· PostUS Equity
$324.35β–Ό $1.01 (βˆ’0.31%)
πŸŒ™ After hours$324.35β–² 0.00%Regular close Β· extended-hours price shown
πŸ””
Track COR
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.3%
7dβ–Ό 4.8%
14dβ–Ό 3.5%
30dβ–² 6.8%
ytdβ–Ό 4.0%
1yβ–Ό 3.3%
🏦Market Cap
$61.90B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
5.1%
Slowing
πŸ“ŠGross Margin
4.0%
Thin
πŸ’΅FCF Margin
1.9%
Thin
βš–οΈP/S Ratio
0.2x
Cheap
Otter Score
68
Fair

Trading Snapshot

Day Range
$320.06 – $327.43
52-Week Range
$244.82 – $377.54
Volume (shares)
1,076,734
Avg Volume (shares)
β€”
Shares Outstanding
190.8M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
$321.33B
Last Q Revenue
$84.75B
P/E Ratio
24.0
P/S Ratio
0.2x
EPS (TTM)
$13.45
Dividend Yield
0.74%
Dilution (1yr)
+0.1%
COR logo

CENCORA INC

COR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$321.3Bβ–² +9.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
3.2%β–² +6.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$3.6Bβ–² +20.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$3.2Bβ–² +7.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
195.3Mβ–² +0.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$6.1Bβ–Ό βˆ’$1.3B YoY
StockOtter Β· stockotter.space

About CENCORA INC

Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100

Analyst Ratings

β“˜
Consensus
Buy
20 analysts
Strong Buy4
Buy10
Hold6
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

Zacks Investment ResearchΒ·12h ago

Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth

Cencora (COR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment ResearchΒ·13h ago

Cencora to Acquire AON in $2.4B Deal to Expand Oncology Network

COR's $2.4B acquisition of AON aims to expand its oncology services platform, strengthen community cancer care and support long-term growth.

GlobeNewsWireΒ·2d ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Surgery Partners, Inc. (Nasdaq – SGRY), Range Resources Corporation (NYSE – RRC), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE – UTZ)

BALA CYNWYD, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith

GlobeNewsWireΒ·7d ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Passage Bio, Inc. (Nasdaq – PASG), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE – UTZ), Finward Bancorp (Nasdaq – FNWD)

BALA CYNWYD,Β Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith

ReutersΒ·7d ago

Cencora to acquire American Oncology Network in $2.4 billion deal

Cencora to acquire American Oncology Network in $2.4 billion deal

Business WireΒ·7d ago

Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology

CONSHOHOCKEN, Pa. & FORT MYERS, Fla.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has signed a definitive agreement to acquire American Oncology Network, Inc. (β€œAON”) (OTCQX: AONC), a physician-led netw